Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future

Par :

Formats :

149,75 €
    • PrésentationCartonné
    • Poids0.712 kg
    • Dimensions16,4 cm × 24,4 cm × 2,2 cm
    • ISBN9789400758650
    • EAN9789400758650
    • Date de parution31/03/2013
    • CollectionAdvances in Predictive, Preventive and Personalised Medicine
    • ÉditeurSpringer

    Résumé

    pThis book will compile a collection of chapters dedicated to varied aspects of PPPM in neuropsychiatric and neurodegenerative diseases. Among the topics to be covered are:brRecent advances in ALS research brNews about Clinical aspects and advanced therapy approaches in personalized treatment of ALS Schizophrenia: New treatments and clinical aspects brPredictive, Preventive and Personalised Medicine in aging macular degeneration brAdvances in Multiple Sclerosis Pharmacogenetics, Tailoring Treatment Efficacy, Safety and Regimen Selection brMultiple sclerosis related biomarkers: perspectives for clinical application brPreventive clinical trials in brain aging: new trends & the need of guidelines brMCI_ clinical guidelines in early diagnosis of dementia brAlzheimer's disease: diagnostics, prognostics and the road to prevention brBiomarkers for early diagnosis of Parkinson's and Alzheimer's diseases brSynucleinopathies, tauopathies, TDP-43 proteinopathies and amyloidosis PSP, MSA and other parkinsonisms/p
    pThis book will compile a collection of chapters dedicated to varied aspects of PPPM in neuropsychiatric and neurodegenerative diseases. Among the topics to be covered are:brRecent advances in ALS research brNews about Clinical aspects and advanced therapy approaches in personalized treatment of ALS Schizophrenia: New treatments and clinical aspects brPredictive, Preventive and Personalised Medicine in aging macular degeneration brAdvances in Multiple Sclerosis Pharmacogenetics, Tailoring Treatment Efficacy, Safety and Regimen Selection brMultiple sclerosis related biomarkers: perspectives for clinical application brPreventive clinical trials in brain aging: new trends & the need of guidelines brMCI_ clinical guidelines in early diagnosis of dementia brAlzheimer's disease: diagnostics, prognostics and the road to prevention brBiomarkers for early diagnosis of Parkinson's and Alzheimer's diseases brSynucleinopathies, tauopathies, TDP-43 proteinopathies and amyloidosis PSP, MSA and other parkinsonisms/p

    A propos de